3[3]Simon A,Besamon M,Shin JM,et al.The ase sites that react selectively with the benzinidazol class of anti-ulcer drugs[J].Gastrcenterology,1993,104(part2):A192.
5 Williams MP,Pounder RE.Review article∶ the pharmacology of rabeprazole[J].Aliment PharmacolTher,1999,13(Suppl 3)∶S3～S10
6 Hongo M,Kimpara T,Moriyama S,et al.Effect of rabeprazole(E3810),a novel protonpump inhibitor,nintragastric pH in healthy volunteers[J].Tohodu J Exp Med,1998,186(1)∶43～45
7 Hirai M, Azuma T, Ito S,et al.A proton pump inhibitor, E3810, has antibacterialactivity through binding to Helicobacter pylori[J].J Gastroenterol,1995 ,30(4)∶461～464
8 Swan SK, Hoyumpa AM, Merritt GJ.Review article∶ the pharmacokinetics ofrabeprazole in health and disease[J].Aliment Pharmacol Ther,1999, 13 (Suppl3)∶S11～S17
9 Yasuda S, Ohnishi A, Ogawa T,et al.Pharmacokinetic properties of E3810, a newproton pump inhibitor,in healthy malevolunteers[J].Int J Clin Pharmacol Ther,1994,32(9)∶466～473
10 Langtry HD, Markham A.Rabeprazole∶ a review of its use in acid-relatedgastrointestinal disorders[J].Drugs,1999 ,58(4)∶725～742
